{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:33:23Z","timestamp":1774362803396,"version":"3.50.1"},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fipaxalparant, a small molecule and negative allosteric modulator of lysophosphatidic acid receptor 1, is being evaluated in phase 2 clinical trials of idiopathic pulmonary fibrosis (IPF) and diffuse cutaneous systemic sclerosis. This phase 1, open\u2010label, crossover, 3\u2010cohort study in healthy adults evaluated mutual drug\u2013drug interactions (DDIs) between fipaxalparant and the IPF medications pirfenidone and nintedanib, as well as the effects of itraconazole (P\u2010glycoprotein inhibitor) and rifampin (potent organic anion transporting polypeptide [OATP] inhibitor) on fipaxalparant. Participants received a single oral dose of fipaxalparant 300 mg. Overall, 16, 20, and 15 participants completed the study in cohorts 1, 2, and 3, respectively. The study demonstrated no relevant mutual DDIs between fipaxalparant and pirfenidone\/nintedanib at clinical doses. There was no effect of itraconazole 400 mg on fipaxalparant exposure. A single rifampin 600 mg dose caused 1.48\u2010fold and 1.86\u2010fold increases in fipaxalparant\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    , respectively. Treatment\u2010emergent adverse events were mild\/moderate with fipaxalparant alone or with the other study drugs. Overall, fipaxalparant absorption in vivo occurs independently of the P\u2010glycoprotein\u2013mediated gut efflux pathway, and fipaxalparant is a clinically relevant OATP substrate. Results of this DDI study will inform the management of concomitant medications of ongoing\/future trials of fipaxalparant.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.1621","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T02:45:27Z","timestamp":1763520327000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacokinetics study to evaluate drug\u2013drug interactions between fipaxalparant and concomitant medications in healthy participants"],"prefix":"10.1002","volume":"15","author":[{"given":"Yang","family":"Song","sequence":"first","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krischan","family":"Hudson","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Ye","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hawley","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brajesh","family":"Pandey","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Zarzoso","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rogowski","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  Deerfield Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Sun","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"A. Rees","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  Gaithersburg Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xin","sequence":"additional","affiliation":[{"name":"Amgen Inc. (formerly Horizon Therapeutics plc)  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R046458"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9173090"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112850"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01980-4"},{"issue":"63","key":"e_1_2_9_6_1","article-title":"LPA1 antagonist BMS\u2010986278 for idiopathic pulmonary fibrosis: preclinical pharmacological in vitro and in vivo evaluation","volume":"54","author":"Murphy B","year":"2019","journal-title":"Eur Respir J"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00828.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1058"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40547"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202405-0977OC"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01826"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.05.040"},{"issue":"1","key":"e_1_2_9_13_1","first-page":"68","article-title":"Pharmacokinetics, metabolism, excretion & mass balance of 14C\u2010HZN\u2010825, a lysophosphatidic acid receptor 1 antagonist, in healthy male subjects","volume":"12","author":"Song Y","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1417"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01060-2018"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13466"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1360"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-017-0459-x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00766-0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100019"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0467-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201706-1301OC"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21454"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1695"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.326"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04374.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007304104"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13613"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199712000-00001"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105932"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02689.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14178"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041662"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12981"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.124.001708"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1424"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30181-4"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5355"},{"issue":"63","key":"e_1_2_9_41_1","article-title":"BBT\u2010877, a potent autotaxin inhibitor in clinical development to treat idiopathic pulmonary fibrosis","volume":"54","author":"Lee G","year":"2019","journal-title":"Eur Respir J"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00064-9"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00430.x"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01678.x"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3343"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.353"},{"key":"e_1_2_9_48_1","first-page":"19","article-title":"The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects","volume":"9","author":"Frost C","year":"2017","journal-title":"Clin Pharmacol"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1621","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:48:21Z","timestamp":1774360101000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpdd.1621"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1621","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"2024-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1621"}}